Topline results for RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, expected in 4Q2025Enrollment continues in CHAPTER-3, a pivotal Phase 3 study of ...

Interface, Inc. (Nasdaq: TILE), the global flooring solutions company and leader in sustainability, today announced that its Board of Directors has declared a regular quarterly cash dividend of $0.02 ...